|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FITM2 |
Gene summary for FITM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FITM2 | Gene ID | 128486 |
| Gene name | fat storage inducing transmembrane protein 2 | |
| Gene Alias | C20orf142 | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q8N6M3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 128486 | FITM2 | HCC1_Meng | Human | Liver | HCC | 2.58e-35 | 3.85e-02 | 0.0246 |
| 128486 | FITM2 | HCC2_Meng | Human | Liver | HCC | 1.15e-03 | 1.57e-02 | 0.0107 |
| 128486 | FITM2 | HCC1 | Human | Liver | HCC | 2.01e-25 | 3.72e+00 | 0.5336 |
| 128486 | FITM2 | HCC2 | Human | Liver | HCC | 1.52e-28 | 3.08e+00 | 0.5341 |
| 128486 | FITM2 | HCC5 | Human | Liver | HCC | 4.17e-35 | 2.32e+00 | 0.4932 |
| 128486 | FITM2 | S014 | Human | Liver | HCC | 4.70e-11 | 4.60e-01 | 0.2254 |
| 128486 | FITM2 | S015 | Human | Liver | HCC | 3.65e-17 | 7.33e-01 | 0.2375 |
| 128486 | FITM2 | S016 | Human | Liver | HCC | 6.51e-21 | 6.43e-01 | 0.2243 |
| 128486 | FITM2 | S028 | Human | Liver | HCC | 2.16e-04 | 1.58e-01 | 0.2503 |
| 128486 | FITM2 | S029 | Human | Liver | HCC | 2.00e-03 | 1.56e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961520 | Thyroid | PTC | response to virus | 162/5968 | 367/18723 | 4.52e-07 | 7.41e-06 | 162 |
| GO:00343408 | Thyroid | PTC | response to type I interferon | 35/5968 | 58/18723 | 7.35e-06 | 8.60e-05 | 35 |
| GO:1903900113 | Thyroid | PTC | regulation of viral life cycle | 72/5968 | 148/18723 | 1.49e-05 | 1.58e-04 | 72 |
| GO:0044409113 | Thyroid | PTC | entry into host | 72/5968 | 151/18723 | 3.48e-05 | 3.29e-04 | 72 |
| GO:0045069112 | Thyroid | PTC | regulation of viral genome replication | 45/5968 | 85/18723 | 4.46e-05 | 4.04e-04 | 45 |
| GO:0046718112 | Thyroid | PTC | viral entry into host cell | 68/5968 | 144/18723 | 8.26e-05 | 7.00e-04 | 68 |
| GO:00713577 | Thyroid | PTC | cellular response to type I interferon | 30/5968 | 52/18723 | 1.06e-04 | 8.56e-04 | 30 |
| GO:00603377 | Thyroid | PTC | type I interferon signaling pathway | 29/5968 | 50/18723 | 1.21e-04 | 9.66e-04 | 29 |
| GO:00516077 | Thyroid | PTC | defense response to virus | 108/5968 | 265/18723 | 1.34e-03 | 7.55e-03 | 108 |
| GO:01405467 | Thyroid | PTC | defense response to symbiont | 108/5968 | 265/18723 | 1.34e-03 | 7.55e-03 | 108 |
| GO:003434110 | Thyroid | PTC | response to interferon-gamma | 59/5968 | 141/18723 | 7.88e-03 | 3.33e-02 | 59 |
| GO:0043903113 | Thyroid | PTC | regulation of biological process involved in symbiotic interaction | 33/5968 | 72/18723 | 9.04e-03 | 3.75e-02 | 33 |
| GO:001603234 | Thyroid | ATC | viral process | 241/6293 | 415/18723 | 5.50e-25 | 2.04e-22 | 241 |
| GO:001905835 | Thyroid | ATC | viral life cycle | 173/6293 | 317/18723 | 9.22e-15 | 5.50e-13 | 173 |
| GO:004440334 | Thyroid | ATC | biological process involved in symbiotic interaction | 153/6293 | 290/18723 | 1.12e-11 | 4.12e-10 | 153 |
| GO:005170134 | Thyroid | ATC | biological process involved in interaction with host | 112/6293 | 203/18723 | 1.93e-10 | 5.76e-09 | 112 |
| GO:001907929 | Thyroid | ATC | viral genome replication | 78/6293 | 131/18723 | 9.92e-10 | 2.55e-08 | 78 |
| GO:005079228 | Thyroid | ATC | regulation of viral process | 90/6293 | 164/18723 | 1.61e-08 | 3.23e-07 | 90 |
| GO:005212633 | Thyroid | ATC | movement in host environment | 94/6293 | 175/18723 | 3.20e-08 | 6.00e-07 | 94 |
| GO:0009615111 | Thyroid | ATC | response to virus | 173/6293 | 367/18723 | 4.23e-08 | 7.71e-07 | 173 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FITM2 | SNV | Missense_Mutation | c.645N>A | p.Asn215Lys | p.N215K | Q8N6M3 | protein_coding | deleterious(0) | benign(0.089) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| FITM2 | insertion | Frame_Shift_Ins | novel | c.72_73insGCGAACCTCGTCTCTTCTAAAA | p.Pro25AlafsTer134 | p.P25Afs*134 | Q8N6M3 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| FITM2 | insertion | Frame_Shift_Ins | novel | c.70_71insAGCCTGTCCAACA | p.Leu24GlnfsTer132 | p.L24Qfs*132 | Q8N6M3 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| FITM2 | SNV | Missense_Mutation | rs370245406 | c.487N>A | p.Ala163Thr | p.A163T | Q8N6M3 | protein_coding | tolerated(0.26) | benign(0.04) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FITM2 | SNV | Missense_Mutation | rs771219892 | c.253N>A | p.Gly85Ser | p.G85S | Q8N6M3 | protein_coding | tolerated(0.43) | possibly_damaging(0.593) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| FITM2 | SNV | Missense_Mutation | novel | c.118N>A | p.Glu40Lys | p.E40K | Q8N6M3 | protein_coding | deleterious(0.02) | possibly_damaging(0.631) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FITM2 | SNV | Missense_Mutation | novel | c.581N>T | p.Ala194Val | p.A194V | Q8N6M3 | protein_coding | deleterious(0) | possibly_damaging(0.611) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FITM2 | SNV | Missense_Mutation | novel | c.152N>G | p.Asn51Ser | p.N51S | Q8N6M3 | protein_coding | tolerated(0.42) | benign(0.112) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| FITM2 | SNV | Missense_Mutation | rs755374181 | c.539N>A | p.Arg180Gln | p.R180Q | Q8N6M3 | protein_coding | tolerated(0.4) | possibly_damaging(0.849) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| FITM2 | SNV | Missense_Mutation | novel | c.499G>A | p.Val167Ile | p.V167I | Q8N6M3 | protein_coding | tolerated(0.19) | benign(0.038) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |